Drugs / TD001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07258407 | Jan 2026 → Mar 2028 expected | metastatic prostate carcinoma | T.O.A.D. Oncology SA | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TD001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07258407 ↗ |
| Modality | Other / unclassified | “an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA)” NCT07258407 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion at protocol-defined doses and schedules” NCT07258407 ↗ |